financetom
AMLX
financetom
/
Healthcare
/
AMLX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Amylyx Pharmaceuticals, Inc.AMLX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
323.84M
Revenue (ttm)
87.37M
Net Income (ttm)
-301.74M
Shares Out
88.60M
EPS (ttm)
-4.43
PE Ratio
n/a
Forward PE
n/a
Dividend
n/a
Ex-Dividend Date
n/a
Volume
297,681
Open
3.490
Previous Close
3.490
Day's Range
3.420 - 3.660
52-Week Range
1.575 - 7.270
Beta
-0.53
Analysts
Buy
Price Target
8.50 (+132.56%)
Earnings Date
May 8, 2025
Description >

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.

The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Copyright 2023-2025 - www.financetom.com All Rights Reserved